Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose

References

• Hall W, Ross J, Lynskey M, Law M, Degenhardt L. How many dependent opioid users are there in Australia?. National Drug & Alcohol Research Centre, Sydney 2000, NDARC Monograph No 44
   Google Scholar
• Dietze P M, Cvetkovski S, Rumbold G R, Miller P. Ambulance attendance at heroin overdose in Melbourne: the establishment of a database of ambulance service records. Drug and Alcohol Review 2000; 19: 27–33
   Web of Science ®Google Scholar
• Cvetkovski S, Dietze P, McElwee P, Miller P. Non-fatal heroin overdose in Melbourne: project report 1999/2000. Turning Point Alcohol and Drug Centre. 2000
   Google Scholar
• Ritter A, Kutin J, Lintzeris L, Bammer G. Expanding treatment options for heroin dependence in Victoria: buprenorphine, LAAM, naltrexone and slow-release oral morphine. Turning Point Alcohol and Drug Centre, Melbourne 1997
   Google Scholar
• Ward J, Mattick R P, Hall W. Methadone maintenance treatment and other opioid replacement therapies, J Ward, R P Mattick, W Hall. Harwood Academic, Amsterdam 1998
   Google Scholar
• Tucker T, Ritter A. Naltrexone in the treatment of heroin dependence: a literature review. Drug and Alcohol Review 2000; 19: 73–82
   Web of Science ®Google Scholar
• O'Brien C P, Greenstein R, Woody G E. Update on naltrexone treatment. The international challenge of drug abuse: NIDA research monograph series, R C Peterson. Department of Health, Education, and Welfare, Rockville, Maryland 1978; 315–320
   Google Scholar
• Judson B A, Carney T M, Goldstein A. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug and Alcohol Dependence 1981; 7: 235–246
   Web of Science ®Google Scholar
• Lerner A, Sigal M, Bacalu A, Shiff R, Burganski I, Gelkopf M. A naltrexone double-blind placebo controlled study in Israel. Israel Journal of Psychiatry and Related Sciences 1992; 29: 36–43
   PubMed Web of Science ®Google Scholar
• Hollister L E. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Archives of General Psychiatry 1978; 35: 335–340
   PubMed Web of Science ®Google Scholar
• Gerra G, Marcato A, Caccavari R, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. Journal of Substance Abuse Treatment 1995; 12: 35–41
   PubMed Web of Science ®Google Scholar
• Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence (Cochrane review). The Cochrane Library. Update Software, Oxford 1999, Issue 4
   Google Scholar
• Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug and Alcohol Dependence 1997; 48: 135–141
   PubMed Web of Science ®Google Scholar
• Hollister L E, Johnson K, Boukhabza D, Gillespie H K. Aversive effects of naltrexone in subjects not dependent on opiates. Drug and Alcohol Dependence 1981; 8: 37–41
   PubMed Web of Science ®Google Scholar
• Mendelson J H, Ellingboe J, Keuhnle J C, Mello N K. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 1979; 3: 231–236
   Web of Science ®Google Scholar
• Crowley T J, Wagner J E, Zerbe G E, Macdonald M J. Naltrexone-induced dysphoria in former opioid addicts. American Journal of Psychiatry 1985; 142: 1081–1084
   PubMed Web of Science ®Google Scholar
• Croop R S, Faulkner E B, Labriola D F. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Archives of General Psychiatry 1997; 54: 1130–1135
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Alterman A I, Hayashida M, O'Brien C P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 1992; 49: 876–880
   PubMed Web of Science ®Google Scholar
• Latt N, Jurd S, Wutzke S. Preliminary findings from a trial of naltrexone in alcohol dependence. Australian Professional Society on Alcohol & Drugs Annual Conference. Melbourne, 2000
   Google Scholar
• Shufman E N, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biological Psychiatry 1994; 35: 935–945
   PubMed Web of Science ®Google Scholar
• San L, Pomarol G, Peri J M, Olle J M, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. British Journal of Addiction 1991; 86: 983–990
   PubMedGoogle Scholar
• Miotto K, McCann M, Rawson R, Frosch D, Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug and Alcohol Dependence 1997; 45: 131–134
   PubMed Web of Science ®Google Scholar
• Rawlins M, Randall M, Meyer R, McNamee H, Mirin S. Aftercare on narcotic antagonists: prospects and problems. International Journal of the Addictions 1976; 11: 501–511
   PubMed Web of Science ®Google Scholar
• Yoburn B C, Goodman R F, Cohen A H. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment. Life Science 1985; 36: 2325–2332
   PubMed Web of Science ®Google Scholar
• Yoburn B C, Nones F A, Adler B. Pharmacodynamic supersensitivity and opioid receptor up-regulation in the mouse. Journal of Pharmacology and Experimental Therapy 1986; 229: 132–135
   Google Scholar
• Tang A H, Collins R J. Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat. European Journal of Pharmacology 1978; 51: 185–186
   PubMed Web of Science ®Google Scholar
• Cornish J W, Henson D, et al. Naltrexone maintenance: effect on morphine sensitivity in normal volunteers. American Journal on Addictions 1993; 2: 34–38
   PubMedGoogle Scholar
• Joe G W, Simpson D D. Mortality rates among opioid addicts in a longitudinal study. American Journal of Public Health 1987; 77: 347–348
   PubMed Web of Science ®Google Scholar
• Caplehorn J, Dalton M, Haldar F, Petrenas A, Nisbet J. Methadone maintenance and addicts' risk of fatal heroin overdose. Substance Use and Misuse 1996; 31: 177–196
   PubMed Web of Science ®Google Scholar
• Bell J R, Young M R, Masterman S C, Morris A, Mattick R P, Bammer G. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Medical Journal of Australia 1999; 171: 26–30
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates on non-fatal overdose. Addiction 1996; 91: 405–411
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J. Overdose risk perceptions and behaviours among heroin users in Sydney, Australia. European Addiction Research 1997; 3: 87–92
   Web of Science ®Google Scholar
• Best D, Gossop M, Lan-Ho M, Finch E, Greenwood J, Strang J. Accidental and deliberate overdose among opiate addicts in methadone maintenance treatment: are deliberate overdoses systematically different?. Drug and Alcohol Review 2000; 19: 213–216
   Web of Science ®Google Scholar